替加环素对多重耐药淋球菌显示杀菌活性并增强小鼠模型清除
针对全球头孢曲松耐药淋球菌威胁,该研究评价替加环素体外及体内抗淋球菌活性。对2011-2024年杭州616株临床分离株药敏试验显示替加环素MIC50为0.125 mg/L、MIC90为0.25 mg/L,时间杀菌试验呈浓度依赖性杀菌,小鼠阴道感染模型高剂量替加环素显著增强细菌清除,支持其作为多重耐药淋病再定位候选药物进一步研究。
要点
- 替加环素对淋球菌MIC50 0.125 mg/L、MIC90 0.25 mg/L,包括头孢曲松高水平耐药株。
- 时间杀菌试验4×MIC可达≥10^5倍杀菌,呈浓度依赖性杀菌活性。
- 小鼠模型高剂量替加环素3-6天清除感染,对照8-12天,临床角色待明确。
核心结论
- 替加环素对淋球菌包括头孢曲松高水平耐药株具有强效快速杀菌活性,体内疗效 robust,支持其作为多重耐药淋病再定位候选药物进一步研究。
研究设计与样本
- 体外药敏试验纳入2011-2024年中国杭州616株临床分离株,时间杀菌试验用2株,棋盘法用21株(10株头孢曲松敏感、11株耐药),并采用小鼠阴道感染模型评价体内活性。
主要发现
- 替加环素MIC50为0.125 mg/L、MIC90为0.25 mg/L,对四环素耐药株(四环素MIC50 2 mg/L、MIC90 64 mg/L)和头孢曲松高水平耐药株(头孢曲松MIC50 0.03 mg/L、MIC90 0.125 mg/L)均有活性。
- 时间杀菌试验(2株)显示浓度依赖性杀菌,4×MIC achieving ≥10^5倍杀菌。
- 小鼠阴道感染模型中高剂量替加环素(25 mg/kg)显著增强细菌清除,3-6天消除感染,对照为8-12天,并大幅降低细菌负荷。
- 棋盘法对21株显示替加环素与头孢曲松为无关相互作用(FICI 1.03-2.56),无拮抗。
关键数值与推荐
- 替加环素对616株淋球菌MIC50 0.125 mg/L、MIC90 0.25 mg/L。
- 四环素耐药株四环素MIC50 2 mg/L、MIC90 64 mg/L。
- 头孢曲松高水平耐药株头孢曲松MIC50 0.03 mg/L、MIC90 0.125 mg/L。
- 替加环素与头孢曲松FICI 1.03-2.56,判为无关相互作用。
临床怎么用
- 提示替加环素可能作为多重耐药淋病的再定位候选药物,但临床角色尚未定义,需进一步研究。
局限性
- 临床角色 remains to be defined,尚需进一步研究确定其临床地位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The global emergence of ceftriaxone-resistant Neisseria gonorrhoeae threatens current first-line treatment and necessitates alternative therapeutic options. Tigecycline, a last-line glycylcycline antibiotic approved for complicated infections, was evaluated for repurposing against N. gonorrhoeae through in vitro and in vivo activity studies. METHODS: Antimicrobial susceptibility testing was performed for 616 clinical isolates (2011-2024) from Hangzhou, China, and bactericidal activity was determined in time-kill assays. A mouse vaginal tract infection model was used to evaluate in vivo tigecycline activity. Chequerboard assays were performed to assess interactions between tigecycline and ceftriaxone. RESULTS: Tigecycline demonstrated potent activity (MIC50: 0.125 mg/L; MIC90: 0.25 mg/L), including against tetracycline-resistant (tetracycline MIC50: 2 mg/L; MIC90: 64 mg/L) and high-level ceftriaxone-resistant (ceftriaxone MIC50: 0.03 mg/L; MIC90: 0.125 mg/L) strains. Time-kill assays (2 strains) revealed concentration-dependent bactericidal activity, with 4×MIC achieving ≥105-fold killing. In the mouse vaginal tract infection model, high-dose tigecycline (25 mg/kg) significantly enhanced bacterial clearance, eliminating infection within 3-6 days compared to 8-12 days in vehicle controls, and substantially reduced bacterial burden. Chequerboard assays against 21 isolates (10 ceftriaxone-susceptible, 11 ceftriaxone-resistant) demonstrated indifferent interactions between tigecycline and ceftriaxone (fractional inhibitory concentration indices 1.03-2.56), indicating no antagonism. CONCLUSIONS: These findings establish that tigecycline exhibits potent, rapid bactericidal activity against N. gonorrhoeae, including against high-level ceftriaxone-resistant strains, with robust in vivo efficacy. They support further investigation of tigecycline as a potential repurposing candidate for multidrug-resistant gonorrhoea, although its clinical role remains to be defined.
引用
- Sun X, Lu W, Ge H, et al. Tigecycline displays bactericidal activity against multidrug-resistant Neisseria gonorrhoeae and enhances clearance from a mouse infection model. J Antimicrob Chemother. 2026. PMID: 42841930. doi:10.1093/jac/dkag337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。